{"id":"W3096278560","doi":"10.1182/blood-2020-133916","title":"Long-Term Follow-up of Ibrutinib Treatment for Rituximab-Refractory Waldenström's Macroglobulinemia: Final Analysis of the Open-Label Substudy of the Phase 3 iNNOVATETM Trial","year":2020,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Rituximab; Ibrutinib; Waldenstrom macroglobulinemia; Internal medicine; Macroglobulinemia; Gastroenterology; Refractory (planetary science); Neutropenia; Progression-free survival; Phases of clinical research; Median follow-up; Surgery; Oncology; Clinical trial; Chemotherapy; Lymphoma; Leukemia; Multiple myeloma; Chronic lymphocytic leukemia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006447938,0.0006584928,0.001527899,0.0003424896,0.000558805,0.001104278,0.0006318737,0.0009723633,0.001111009],"category_scores_gemma":[0.003549067,0.0003159094,0.001632853,0.0005811667,0.0004054383,0.0007559558,0.000648322,0.001666121,0.000317235],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007733853,"about_ca_system_score_gemma":0.0008065358,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001081226,"about_ca_topic_score_gemma":0.002591492,"domain_scores_codex":[0.9980624,0.001052479,0.0001901447,0.0002616017,0.0002309428,0.0002024468],"domain_scores_gemma":[0.9964744,0.0008589494,0.00123119,0.0004124639,0.0004089228,0.0006139525],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5776871,0.005558058,0.3215978,0.001022538,0.01214408,0.000281953,0.0006652064,0.001300854,0.00727319,0.0002002042,0.005385804,0.06688323],"study_design_scores_gemma":[0.09220897,0.07239471,0.8152804,0.0002415142,0.009250847,0.0005783582,0.0002475518,0.001391169,0.001896611,0.0002583489,0.006170472,0.00008119229],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9920365,0.003744568,0.0002843141,0.0001515904,0.00004636058,0.0004789536,0.002318523,0.00001597949,0.0009231979],"genre_scores_gemma":[0.9923047,0.0006320089,0.0002822661,0.0002957991,0.0001052959,0.0005789684,0.005550916,0.000006126124,0.0002437825],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006447938,"threshold_uncertainty_score":0.03410035,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1374803297596642,"score_gpt":0.3988400037161458,"score_spread":0.2613596739564815,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}